Literature DB >> 28146139

Is cardiovascular risk in women with PCOS a real risk? Current insights.

Georgios Papadakis1, Eleni Kandaraki2, Olga Papalou3, Andromachi Vryonidou2, Evanthia Diamanti-Kandarakis4.   

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive aged women. PCOS incorporates not only symptoms related to the reproductive system but also a clustering of systemic metabolic abnormalities that are linked with increased risk for cardiovascular disease (CVD). More specifically, metabolic aberrations such as impaired glucose and lipid metabolism, accompanied by increased low-grade inflammation as well as elevated coagulation factors appear to contribute to the increased cardiovascular risk. Even though many studies have indicated a rise in surrogate biomarkers of CVD in women with PCOS, it is still doubtful to what extent and magnitude this elevation can be translated to real cardiovascular events. Furthermore, the cardiovascular risk factors appear to vary significantly in the different phenotypes of the syndrome. Women with PCOS have the potential for early atherosclerosis, myocardial and endothelial dysfunction. Whether PCOS women are at real cardiovascular risk compared to controls remains between the verge of theoretical and real threat for the PCOS women at any age but particularly in the post-menopausal state. Interestingly, although the presence of the CVD risk factors is well documented in PCOS women, their combination on different phenotypes may play a role, which eventually results in a spectrum of clinical manifestations of CVD with variable degree of severity. The present manuscript aims to review the interaction between PCOS and the combination of several cardiovascular risk factors.

Entities:  

Mesh:

Year:  2017        PMID: 28146139     DOI: 10.23736/S0391-1977.17.02609-8

Source DB:  PubMed          Journal:  Minerva Endocrinol        ISSN: 0391-1977            Impact factor:   2.184


  8 in total

Review 1.  A review on inositol's potential in cyclic disturbances of adipose-endocrinology-associated polycystic ovary syndrome.

Authors:  Waleed Hassan Almalki
Journal:  Mol Cell Biochem       Date:  2021-03-23       Impact factor: 3.396

Review 2.  Updates on Molecular Targets and Epigenetic-Based Therapies for PCOS.

Authors:  Viktor V Smirnov; Narasimha M Beeraka; Dmitry Yu Butko; Vladimir N Nikolenko; Sergey A Bondarev; Evgeniy E Achkasov; Mikhail Y Sinelnikov; P R Hemanth Vikram
Journal:  Reprod Sci       Date:  2022-06-28       Impact factor: 2.924

3.  Haptoglobin levels, but not Hp1-Hp2 polymorphism, are associated with polycystic ovary syndrome.

Authors:  Laura M L Carvalho; Cláudia N Ferreira; Daisy K D de Oliveira; Kathryna F Rodrigues; Rita C F Duarte; Márcia F A Teixeira; Luana B Xavier; Ana Lúcia Candido; Fernando M Reis; Ieda F O Silva; Fernanda M F Campos; Karina B Gomes
Journal:  J Assist Reprod Genet       Date:  2017-09-13       Impact factor: 3.412

Review 4.  Cardiometabolic risk in polycystic ovary syndrome.

Authors:  Katica Bajuk Studen; Marija Pfeifer
Journal:  Endocr Connect       Date:  2018-05-29       Impact factor: 3.335

5.  Decreased deiodinase activity after glucose load could lead to atherosclerosis in euthyroid women with polycystic ovary syndrome.

Authors:  Agnieszka Adamska; Anna Krentowska; Agnieszka Łebkowska; Justyna Hryniewicka; Monika Leśniewska; Marcin Adamski; Irina Kowalska
Journal:  Endocrine       Date:  2019-04-03       Impact factor: 3.633

6.  Increased serum fetuin-B concentration is associated with HOMA-β and indices of liver steatosis in women with polycystic ovary syndrome: a pilot study.

Authors:  Agnieszka Adamska; Aleksandra Maria Polak; Anna Krentowska; Agnieszka Łebkowska; Justyna Hryniewicka; Monika Leśniewska; Irina Kowalska
Journal:  Endocr Connect       Date:  2019-08       Impact factor: 3.335

7.  The cardiovascular risk profile of middle-aged women with polycystic ovary syndrome.

Authors:  Cindy Meun; Marlise N Gunning; Yvonne V Louwers; Henrike Peters; Jolien Roos-Hesselink; Jeanine Roeters van Lennep; Oscar-Leonel Rueda Ochoa; Yolande Appelman; Nils Lambalk; Eric Boersma; Maryam Kavousi; Bart Cjm Fauser; Joop Se Laven
Journal:  Clin Endocrinol (Oxf)       Date:  2019-11-24       Impact factor: 3.478

Review 8.  Metabolomic Insight into Polycystic Ovary Syndrome-An Overview.

Authors:  Anna Rajska; Magdalena Buszewska-Forajta; Dominik Rachoń; Michał Jan Markuszewski
Journal:  Int J Mol Sci       Date:  2020-07-09       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.